Current Diagnostics May Mischaracterize Tumors1-6
Actor portrayal
Image-based glioma management is complicated by treatment-related changes, which may resemble tumor progression and impact clinical decision-making1-6
18%-30%
pseudoprogression, which mimics tumor growth1-3
Up to
30%
radiation necrosis, which mimics tumor growth but is actually cell death due to treatment1,4-6
20%-60%
pseudoresponse, which mimics tumor shrinkage but is actually reduced contrast due to vascular changes5
18F-FET PET imaging: more than 20 years of European experience overcoming diagnostic limitations7
Supplementing MRI with 18F-FET PET offers a clear path forward.8-10
90% sensitivity and specificity when used with MRI8
Low background uptake in normal brain tissue9
Tumor-specific targeting9
Capable of distinguishing tumor recurrence from treatment-related change9
Long half-life9,10
Pixclara® (18F-FET) PET demonstrated strong diagnostic performance across multiple studies.10
View Efficacy Data18F-FET, 18F-fluoro-ethyl-tyrosine; MRI, magnetic resonance imaging; PET, positron emission tomography.